Il Canadian Urological Association ha provveduto ad aggiornare le linee guida pubblicate nel 2018 e riviste nel 2010 sulla gestione dei sintomi del tratto urinario inferiore maschile (MLUTS) secondari all’iperplasia prostatica benigna (BPH).
Leggi gli articoli in full text:
- UPDATE – 2022 Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH).
Elterman, D. ., Aubé-Peterkin, M., Evans, H. ., Elmansy, H. ., Meskawi, M. ., Zorn, K. C. ., & Bhojani, N.
Canadian Urological Association Journal, 16(8), 245–56. https://doi.org/10.5489/cuaj.7906
Articoli correlati:
- Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update.
Nickel JC, Aaron L, Barkin J, Elterman D, Nachabé M, Zorn KC.
Can Urol Assoc J. 2018 Oct;12(10):303-312. doi: 10.5489/cuaj.5616. PMID: 30332601; PMCID: PMC6192748. - 2010 Update: Guidelines for the management of benign prostatic hyperplasia.
Nickel JC, Méndez-Probst CE, Whelan TF, Paterson RF, Razvi H.
Can Urol Assoc J. 2010 Oct;4(5):310-6. doi: 10.5489/cuaj.10124. PMID: 20944799; PMCID: PMC2950766. - Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia – Cochrane Library
- Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta‐analysis – Cochrane Library
- Phosphodiesterase inhibitors for treatment of urinary problems in men with benign prostatic hyperplasia – Cochrane Library
- Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary retention (UNBLOCS): a randomised controlled trial – The Lancet
